title: High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
abstract: The PI3/AKT pathway is up-regulated in acute myeloid leukemia (AML), but its prognostic relevance in cytogenetically normal AML (CN-AML) is unclear. We evaluated RNA levels of AKT and two downstream substrates (FOXO3a-p27) in 110 de novo CN-AML, included in the Spanish PETHEMA therapeutic protocols. Patients with high FOXO3a gene expression displayed shorter OS (p=0.015) and RFS (p=0.048) than low FOXO3a expressers. Features selected in the multivariate analysis as having an independent prognostic value for a shorter survival were WBC>50x10(9)/L, age >65 years and high FOXO3a expression. We concluded that FOXO3a assessment could contribute to improve the molecular-based risk stratification in CN-AML.
authors.affiliation: Hospital Universitario, Salamanca, Spain; Centro de Investigación Del Cáncer-IBMCC (USAL-CSIC) of Salamanca, Spain. cmsantamaria@usal.es
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Santamaría
authors.forename: Maria C
authors.initials: MC
authors.lastname: Chillón
authors.forename: Ramón
authors.initials: R
authors.lastname: García-Sanz
authors.forename: Cristina
authors.initials: C
authors.lastname: Pérez
authors.forename: María D
authors.initials: MD
authors.lastname: Caballero
authors.forename: Fernando
authors.initials: F
authors.lastname: Ramos
authors.forename: Alfonso García
authors.initials: AG
authors.lastname: de Coca
authors.forename: José M
authors.initials: JM
authors.lastname: Alonso
authors.forename: Pilar
authors.initials: P
authors.lastname: Giraldo
authors.forename: Teresa
authors.initials: T
authors.lastname: Bernal
authors.forename: José A
authors.initials: JA
authors.lastname: Queizán
authors.forename: Juan N
authors.initials: JN
authors.lastname: Rodriguez
authors.forename: Pascual
authors.initials: P
authors.lastname: Fernández-Abellán
authors.forename: Abelardo
authors.initials: A
authors.lastname: Bárez
authors.forename: María J
authors.initials: MJ
authors.lastname: Peñarrubia
authors.forename: María B
authors.initials: MB
authors.lastname: Vidriales
authors.forename: Ana
authors.initials: A
authors.lastname: Balanzategui
authors.forename: María E
authors.initials: ME
authors.lastname: Sarasquete
authors.forename: Miguel
authors.initials: M
authors.lastname: Alcoceba
authors.forename: Joaquín
authors.initials: J
authors.lastname: Díaz-Mediavilla
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: Marcos
authors.initials: M
authors.lastname: Gonzalez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011379:Prognosis; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D016019:Survival Analysis; D055815:Young Adult
chemical_list: C499517:FOXO3 protein, human; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt